

# **Novartis reports new Phase III data showing secukinumab (AIN457) improved moderate-to-severe plaque psoriasis in patients**

Mar 22, 2014

---

**Source URL:** <https://qa1.novartis.us/news/media-releases/novartis-reports-new-phase-iii-data-showing-secukinumab-ain457-improved-moderate-severe-plaque-psoriasis-patients-0>

## **List of links present in page**

1. <https://qa1.novartis.us/news/media-releases/novartis-reports-new-phase-iii-data-showing-secukinumab-ain457-improved-moderate-severe-plaque-psoriasis-patients-0>